---
title: Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients
nct_id: NCT00698399
overall_status: COMPLETED
sponsor: Vanderbilt University Medical Center
study_type: OBSERVATIONAL
primary_condition: Liver Transplant
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00698399.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00698399"
ct_last_update_post_date: 2018-02-28
last_seen_at: "2026-05-12T06:37:01.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients

**Official Title:** Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients, Phase II

**NCT ID:** [NCT00698399](https://clinicaltrials.gov/study/NCT00698399)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Vanderbilt University Medical Center
- **Collaborators:** University of California, San Francisco
- **Conditions:** Liver Transplant
- **Start Date:** 2008-03
- **Completion Date:** 2010-02-02
- **CT.gov Last Update:** 2018-02-28

## Brief Summary

This is an observational study examining serum markers in patients who are undergoing either a cadaveric liver transplant or a living related liver transplant.

## Detailed Description

The Departments of Anesthesiology are conducting an observational trial of markers in the serum of patients who are undergoing liver transplantation surgery. This study will utilize the biological markers, trimethylamine-N-oxide (TMAO), NGAL, and cystatin-C, sensitive markers of renal medullary injury in the blood and allantoin, a marker of oxidative stress as indicators of renal injury in a kidney during liver transplants. It is hypothesized that: (1) these markers are less pronounced in living donor liver transplant recipient patients than in cadaveric liver transplant recipients, and (2) these markers are less pronounced in cadaveric liver transplant recipients in which a "piggy-back" technique was used versus recipients in which a total venous occlusion technique was used. This study will be done in a multi-center format, along with researchers at UCSF

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) Class I-V.
* Patient is undergoing elective Liver Transplant Surgery.
* Patient is an adult, 18 years old or older.

Exclusion Criteria:

* Patients \< 18 Years of Age
* Patients who are pregnant
```

## Arms

- **1** — Live Donor
- **2** — Cadaveric Donor

## Locations (1)

- Vanderbilt University Medical Center, Nashville, Tennessee, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.vanderbilt university medical center|nashville|tennessee|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00698399.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00698399*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*